Methods for the prevention and/or the treatment of neurological disorders
CA 2486302 A1 · Owner: Faust Pharmaceuticals · Inventors: Neuville, Pascal
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to the use of substrates of an UDPglucuronosyltransferase (UGT) and salts thereof for the prevention and /or , the treatment of neurological disorders. In preferred embodiment the present , invention relates to the use of substrates of at least an UDPglucuronosyltransferase (UGT) expressed in brain and salts thereof for the , prevention and /or the treatment of neurological disorders. It further relates to the use of said substrates, and salts thereof for preventing and/or , treating glutamate cytotoxicity and more specifically of glutamate induced neurological disorders. Additionally, it concerns the use of said substrates and salts thereof, for making drugs …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 16, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 16, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 16, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.